Epcoritamab SC With Rituximab plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma, Including Patients With POD24: Updated Results From EPCORE NHL-2

Reid W. Merryman; David Belada; Anna Sureda; Sirpa Leppa; Joost S. P. Vermaat; Harald Holte; Martin Hutchings; Pieternella Lugtenburg; Sven de Vos; Pau Abrisqueta; Marcel Nijland; Jacob Haaber Christensen; Bjorn E. Wahlin; Kim M. Linton; Wang Liwei; Aqeel Abbas; Ali Rana; Syed Quadri; Lorenzo Falchi

Epcoritamab SC With Rituximab plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma, Including Patients With POD24: Updated Results From EPCORE NHL-2

Reid W. Merryman, David Belada, Anna Sureda, Sirpa Leppa, Joost S. P. Vermaat, Harald Holte, Martin Hutchings, Pieternella Lugtenburg, Sven de Vos, Pau Abrisqueta, Marcel Nijland, Jacob Haaber Christensen, Bjorn E. Wahlin, Kim M. Linton, Wang Liwei, Aqeel Abbas, Ali Rana, Syed Quadri, Lorenzo Falchi

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	S37-S38
Number of pages	2
Journal	American Journal of Hematology
Volume	98
Publication status	Published - Oct 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Merryman, R. W., Belada, D., Sureda, A., Leppa, S., Vermaat, J. S. P., Holte, H., Hutchings, M., Lugtenburg, P., de Vos, S., Abrisqueta, P., Nijland, M., Christensen, J. H., Wahlin, B. E., Linton, K. M., Liwei, W., Abbas, A., Rana, A., Quadri, S., & Falchi, L. (2023). Epcoritamab SC With Rituximab plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma, Including Patients With POD24: Updated Results From EPCORE NHL-2. American Journal of Hematology, 98, S37-S38.

@article{29b257d6304345269fbafdfdcd9ff341,

title = "Epcoritamab SC With Rituximab plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma, Including Patients With POD24: Updated Results From EPCORE NHL-2",

author = "Merryman, {Reid W.} and David Belada and Anna Sureda and Sirpa Leppa and Vermaat, {Joost S. P.} and Harald Holte and Martin Hutchings and Pieternella Lugtenburg and {de Vos}, Sven and Pau Abrisqueta and Marcel Nijland and Christensen, {Jacob Haaber} and Wahlin, {Bjorn E.} and Linton, {Kim M.} and Wang Liwei and Aqeel Abbas and Ali Rana and Syed Quadri and Lorenzo Falchi",

year = "2023",

month = oct,

language = "English",

volume = "98",

pages = "S37--S38",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "John Wiley & Sons Ltd",

}

Merryman, RW, Belada, D, Sureda, A, Leppa, S, Vermaat, JSP, Holte, H, Hutchings, M, Lugtenburg, P, de Vos, S, Abrisqueta, P, Nijland, M, Christensen, JH, Wahlin, BE, Linton, KM, Liwei, W, Abbas, A, Rana, A, Quadri, S & Falchi, L 2023, 'Epcoritamab SC With Rituximab plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma, Including Patients With POD24: Updated Results From EPCORE NHL-2', American Journal of Hematology, vol. 98, pp. S37-S38.

Epcoritamab SC With Rituximab plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma, Including Patients With POD24: Updated Results From EPCORE NHL-2. / Merryman, Reid W.; Belada, David; Sureda, Anna et al.
In: American Journal of Hematology, Vol. 98, 10.2023, p. S37-S38.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Epcoritamab SC With Rituximab plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma, Including Patients With POD24

T2 - Updated Results From EPCORE NHL-2

AU - Merryman, Reid W.

AU - Belada, David

AU - Sureda, Anna

AU - Leppa, Sirpa

AU - Vermaat, Joost S. P.

AU - Holte, Harald

AU - Hutchings, Martin

AU - Lugtenburg, Pieternella

AU - de Vos, Sven

AU - Abrisqueta, Pau

AU - Nijland, Marcel

AU - Christensen, Jacob Haaber

AU - Wahlin, Bjorn E.

AU - Linton, Kim M.

AU - Liwei, Wang

AU - Abbas, Aqeel

AU - Rana, Ali

AU - Quadri, Syed

AU - Falchi, Lorenzo

PY - 2023/10

Y1 - 2023/10

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:001098086400060&DestLinkType=FullRecord&DestApp=WOS_CPL

M3 - Meeting Abstract

SN - 0361-8609

VL - 98

SP - S37-S38

JO - American Journal of Hematology

JF - American Journal of Hematology

ER -

Epcoritamab SC With Rituximab plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma, Including Patients With POD24: Updated Results From EPCORE NHL-2

UN SDGs

Other files and links

Cite this